Published in Gene Therapy Weekly, May 26th, 2011
"pSilencer4.1-shRNA targeting survivin (pSilencer4.1-s) and pSilencer4.1-NC (negative control) vectors were previously constructed [by us. Two colorectal cancer cell lines (LoVo or HCT-8) were collected and used for forming...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2011-05-26)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.